SCHEMBL2884836

SCHEMBL2884836

Brc1ccc(COC2CCCCO2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ICAM1 P05362 1/20 0.42
SELE P16581 1/20 0.42
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM4C Q9H3R0 1/20 0.39
IDO1 P14902 2/20 0.39
CARM1 Q86X55 1/20 0.39
PRMT6 Q96LA8 1/20 0.39
RAB9A P51151 2/20 0.38
MAPT P10636 1/20 0.38
KDM4E B2RXH2 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
CREBBP Q92793 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
EP300 Q09472 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4079719 1.00 ICAM1 (0.42) ICAM1SELEALDH1A1MEN1KMT2A
SCHEMBL3999018 0.87 ICAM1 (0.42) ICAM1SELEALDH1A1MEN1KMT2A
SCHEMBL4317051 0.85 ICAM1 (0.45) ICAM1SELEALDH1A1MEN1KMT2A
SCHEMBL4078714 0.84 KDM4C (0.49) MEN1KMT2AKDM4CRAB9AL3MBTL1
SCHEMBL4079349 0.84 KDM4C (0.49) MEN1KMT2AKDM4CRAB9AL3MBTL1
SCHEMBL2830733 0.84 ICAM1 (0.44) ICAM1SELEALDH1A1MEN1KMT2A
SCHEMBL14065905 0.84 ICAM1 (0.42) ICAM1SELEMEN1KMT2ASMN1; SMN2
SCHEMBL12141797 0.84 ICAM1 (0.42) ICAM1SELEALDH1A1MEN1KMT2A
SCHEMBL13953724 0.84 ICAM1 (0.42) ICAM1SELEALDH1A1MEN1KMT2A
SCHEMBL1732484 0.84 ALDH1A1 (0.46) ICAM1SELEALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12428430-B2 Oxabicyclo acids as LPA antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2025-09-30 US disclosed
US-20250059220-A1 SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2025-02-20 US disclosed
WO-2023121939-A1 SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2023-06-29 WO disclosed
WO-2023121939-A1 SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2023-06-29 WO disclosed
CN-116323612-A Tricyclic urea compounds as JAK 2V 617F inhibitors 因赛特公司 2023-06-23 CN disclosed
EP-3853232-B1 OXABICYCLO ACIDS AS LPA ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2023-03-01 EP disclosed
US-20210317131-A1 OXABICYCLO ACIDS AS LPA ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY 2021-10-14 US disclosed
CN-113366000-A Oxabicyclic acids as LPA antagonists 百时美施贵宝公司 2021-09-07 CN disclosed
EP-3853232-A1 OXABICYCLO ACIDS AS LPA ANTAGONISTS Bristol-Myers Squibb Company (US) 2021-07-28 EP disclosed
WO-2020060914-A1 OXABICYCLO ACIDS AS LPA ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2020-03-26 WO disclosed
US-4886804-A HYPERTENSIVE, CARDIOTONIC, HYPERGLYCEMIC, ANTIARRHYTHMIA AGENTS BAYER AKTIENGESELLSCHAFT (DE) 1989-12-12 US disclosed
EP-0308785-A2 Dihydropyridine ethers, processes for their preparation and their utilisation BAYER AG (DE) 1989-03-29 EP disclosed
EP-0287866-A1 Substituted 1,4-dihydropyridines, method for their preparation and their use BAYER AG (DE) 1988-10-26 EP disclosed
US-4465632-A Process for preparing 1-6-and 2-substituted-1-carba-2-penem-3-carboxylic acids MERCK & CO., INC. (US) 1984-08-14 US disclosed
EP-0010316-B1 1-, 6- AND 2-SUBSTITUTED-1-CARBA-2-PENEM-3-CARBOXYLIC ACIDS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME MERCK & CO. INC. (US) 1983-10-05 EP disclosed
US-4260627-A 1-, 6- And 2-substituted-1-carba-2-penem-3-carboxylic acids MERCK & CO., INC. (US) 1981-04-07 US disclosed
EP-0010316-A1 1-, 6- and 2-substituted-1-carba-2-penem-3-carboxylic acids, process for preparing the same and pharmaceutical compositions containing the same MERCK & CO. INC. (US) 1980-04-30 EP disclosed
US-4064132-A ANTIINFLAMMATORY AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 1977-12-20 US disclosed
US-4060528-A ANTIINFLAMMATORY JANSSEN PHARMACEUTICA N.V. (BE) 1977-11-29 US disclosed
US-4035376-A ESTERS, AMIDES, HYDROXAMIC ACIDS, ANTIINFLAMMATORY JANSSEN PHARMACEUTICA N.V. (BE) 1977-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12428430-B2 Oxabicyclo acids as LPA antagonists LPAR1, LPAR2, LPAR3 ICAM1 2064/4885SELE 2027/4885ALDH1A1 1885/4885
US-20210317131-A1 OXABICYCLO ACIDS AS LPA ANTAGONISTS LPAR1, LPAR2, LPAR3 ICAM1 2064/4885SELE 2027/4885ALDH1A1 1885/4885
US-20250059220-A1 SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF SULT1E1, TPMT, SULT1A1 ICAM1 4870/4885SELE 2816/4885ALDH1A1 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.